author-photo

Wei Chen

Center for Drug Evaluation and Research

3

Papers

365

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (79)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (196)
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis

2012 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (90)